Stay updated on Omalizumab in Multi-Allergen OIT Clinical Trial

Sign up to get notified when there's something new on the Omalizumab in Multi-Allergen OIT Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Omalizumab in Multi-Allergen OIT Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page’s footer revision/version number was updated from v3.5.0 to v3.5.3.
    Difference
    0.0%
    Check dated 2026-04-26T08:17:04.000Z thumbnail image
  3. Check
    26 days ago
    No Change Detected
  4. Check
    47 days ago
    Change Detected
    Summary
    Website revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-21T08:01:09.000Z thumbnail image
  5. Check
    62 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.4.3 and the previous Revision: v3.4.2 label has been removed.
    Difference
    0.0%
    Check dated 2026-03-06T19:19:32.000Z thumbnail image
  6. Check
    83 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2.
    Difference
    0.0%
    Check dated 2026-02-13T12:43:19.000Z thumbnail image
  7. Check
    90 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.0 to v3.4.1.
    Difference
    0.0%
    Check dated 2026-02-06T09:12:37.000Z thumbnail image
  8. Check
    105 days ago
    Change Detected
    Summary
    Changed the label for the update timestamp from 'Last Update Posted (Estimated)' to 'Last Update Posted' on the study record. This alters how update times are displayed but does not affect the underlying study data or eligibility criteria.
    Difference
    0.0%
    Check dated 2026-01-22T09:28:59.000Z thumbnail image

Stay in the know with updates to Omalizumab in Multi-Allergen OIT Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Omalizumab in Multi-Allergen OIT Clinical Trial page.